Dimensional Fund Advisors LP Grows Holdings in Solventum Corporation $SOLV

Key Points

• Dimensional Fund Advisors increased its Solventum stake by 44% during the first quarter, acquiring 236,659 additional shares and bringing its total holdings to 774,683 shares worth approximately $50.6 million.
• Solventum shares opened at $85.69, near their 52-week high of $88.65. The company beat quarterly earnings and revenue expectations, reporting $1.48 in EPS and $2.01 billion in revenue, although revenue declined 3% year over year.
• Analyst sentiment is mixed but improving: seven analysts rate the stock Buy, five Hold, and one Sell. Recent price targets range from $90 to $95, while the consensus target is $86 and the overall consensus rating is Hold.

Dimensional Fund Advisors LP increased its holdings in Solventum Corporation (NYSE:SOLV - Free Report) by 44.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 774,683 shares of the company's stock after acquiring an additional 236,659 shares during the quarter. Dimensional Fund Advisors LP owned about 0.45% of Solventum worth $50,576,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Assetmark Inc. boosted its stake in Solventum by 21.4% during the fourth quarter. Assetmark Inc. now owns 725 shares of the company's stock worth $57,000 after acquiring an additional 128 shares in the last quarter. BOKF NA grew its holdings in Solventum by 6.9% in the third quarter. BOKF NA now owns 2,193 shares of the company's stock worth $160,000 after purchasing an additional 141 shares during the period. Smartleaf Asset Management LLC increased its stake in shares of Solventum by 23.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 744 shares of the company's stock valued at $60,000 after purchasing an additional 142 shares in the last quarter. Deseret Mutual Benefit Administrators increased its stake in shares of Solventum by 39.5% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 516 shares of the company's stock valued at $41,000 after purchasing an additional 146 shares in the last quarter. Finally, HB Wealth Management LLC increased its stake in shares of Solventum by 3.5% during the first quarter. HB Wealth Management LLC now owns 4,292 shares of the company's stock valued at $280,000 after purchasing an additional 147 shares in the last quarter.

Solventum Trading Up 0.3%

Shares of NYSE SOLV opened at $85.69 on Monday. The firm's 50 day moving average price is $78.41 and its 200-day moving average price is $74.20. Solventum Corporation has a 52-week low of $62.38 and a 52-week high of $88.65. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. The company has a market cap of $14.84 billion, a PE ratio of 10.50, a P/E/G ratio of 1.32 and a beta of 0.66.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter last year, the firm earned $1.34 earnings per share. The firm's quarterly revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, equities research analysts expect that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Analyst Ratings Changes

SOLV has been the topic of a number of analyst reports. Wedbush began coverage on Solventum in a research report on Friday, May 15th. They issued an "outperform" rating and a $94.00 price target on the stock. BTIG Research reaffirmed a "buy" rating and set a $91.00 price objective on shares of Solventum in a research report on Monday, July 13th. Stifel Nicolaus reduced their price objective on Solventum from $105.00 to $90.00 and set a "buy" rating for the company in a research report on Wednesday, May 6th. Weiss Ratings upgraded Solventum from a "hold (c)" rating to a "hold (c+)" rating in a research note on Friday, July 17th. Finally, UBS Group raised Solventum from a "neutral" rating to a "buy" rating and set a $95.00 target price on the stock in a report on Tuesday, July 28th. Seven investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $86.00.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source